Uganda is to drop chloroquine as the first line of treatment for malariain a number of districts where the disease has high rates of resistance to the drug, the country's Director General of Health Services, Francis Omaswa, has said. However, this would not be a blanket change of treatment strategy, he said; chloroquine will maintain its first-line position in districts where it still works well.
Resistance is highest in Kampala and Moroto, where chloroquine fails to cure over 60% of malaria cases, and lowest in Rukungiri, where it still successfully treats 98%, said Prof Omaswa. In districts where resistance is high, the first line of treatment will be a combination of Fansidar (pyrimethamine sulfadoxine) and chloroquine, he said; if this combination fails, quinine is to be used.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze